GSK pays $7.5 million milestone to Isis Pharma under antisense deal; says FDA accepts Anoro Ellipta NDA

20 February 2013

US biotech firm Isis Pharmaceuticals (Nasdaq: ISIS) says that it has earned a $7.5 million milestone payment from UK pharma giant GlaxoSmithKline (LSE: GSK) related to the initiation of a Phase II/III clinical study for ISIS-TTRRx, an antisense drug in development with GSK for the treatment of transthyretin (TTR) amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.

Isis and GSK recently amended the clinical development plan and financial terms relating to ISIS-TTRRx to support this registration-directed Phase II/III clinical study on ISIS-TTRRx (The Pharma Letter November 6, 2012). The compound also gained US Food and Drug Administration fast-track status last year (TPL December 14, 2012).

Further $50 million in the offing

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK